Affinity Asset Advisors LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX)

Affinity Asset Advisors LLC bought a new position in Nkarta, Inc. (NASDAQ:NKTX) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 200,000 shares of the company’s stock, valued at approximately $1,182,000. Affinity Asset Advisors LLC owned 0.40% of Nkarta at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NKTX. Vanguard Personalized Indexing Management LLC increased its stake in shares of Nkarta by 22.5% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 14,226 shares of the company’s stock worth $94,000 after acquiring an additional 2,613 shares in the last quarter. Wasatch Advisors LP lifted its position in Nkarta by 13.6% in the 4th quarter. Wasatch Advisors LP now owns 2,099,699 shares of the company’s stock valued at $13,858,000 after acquiring an additional 251,795 shares in the last quarter. Superstring Capital Management LP bought a new position in Nkarta during the 4th quarter valued at about $2,293,000. Commodore Capital LP purchased a new stake in Nkarta during the 4th quarter valued at $18,018,000. Finally, Boxer Capital LLC purchased a new stake in Nkarta in the 4th quarter worth approximately $9,504,000. Institutional investors own 80.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of research reports. Raymond James upgraded shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a report on Wednesday, August 14th. HC Wainwright cut their target price on Nkarta from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $13.00 price target on shares of Nkarta in a research note on Wednesday, August 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $18.20.

Nkarta Trading Down 2.3 %

Shares of NASDAQ NKTX opened at $4.75 on Wednesday. The stock has a 50 day moving average price of $5.75 and a 200 day moving average price of $7.03. Nkarta, Inc. has a 52-week low of $1.28 and a 52-week high of $16.24.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.15. Research analysts predict that Nkarta, Inc. will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Nkarta

In other Nkarta news, insider Alicia J. Hager sold 3,396 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $8.00, for a total transaction of $27,168.00. Following the completion of the sale, the insider now directly owns 103,819 shares of the company’s stock, valued at $830,552. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 8.70% of the stock is owned by insiders.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.